



PHS PUBLIC ACCESS

Author manuscript

Am J Obstet Gynecol. Author manuscript; available in PMC 2016 August 02.

Published in final edited form as:

Am J Obstet Gynecol. 2015 May ; 212(5): 591.e1–591.e8. doi:10.1016/j.ajog.2015.03.006.

Laparoscopic hysterectomy with morcellation versus abdominal hysterectomy for presumed fibroids in premenopausal women: a decision analysis

Matthew T. SIEDHOFF, MD, MSCR¹, Stephanie B. WHEELER, PhD, MPH², Ms. Sarah E. RUTSTEIN, BA², Elizabeth J. GELLER, MD¹, Kemi M. DOLL, MD¹, Jennifer M. WU, MD, MPH¹, and Daniel L. CLARKE-PEARSON, MD¹

¹ Department of Obstetrics & Gynecology, The University of North Carolina at Chapel Hill

² Gillings School of Global Public Health, The University of North Carolina at Chapel Hill

Abstract

Objective—To model outcomes in laparoscopic hysterectomy with morcellation compared to abdominal hysterectomy for the presumed fibroid uterus, examining short-and long-term complications, as well as mortality.

Study Design—A decision tree was constructed to compare outcomes for a hypothetical cohort of 100,000 premenopausal women undergoing hysterectomy for presumed fibroids over a 5-year time horizon. Parameter and quality of life utility estimates were determined from published literature for postoperative complications, leiomyosarcoma incidence, death related to leiomyosarcoma, and procedure-related death.

Results—The decision analysis predicted fewer overall deaths with laparoscopic hysterectomy compared to abdominal hysterectomy (98 vs. 103 per 100,000). While there were more deaths from leiomyosarcoma following laparoscopic hysterectomy (86 vs. 71 per 100,000), there were more hysterectomy-related deaths with abdominal hysterectomy (32 vs. 12 per 100,000). The laparoscopic group had lower rates of transfusion (2,400 vs. 4,700 per 100,000), wound infection (1,500 vs 6,300 per 100,000), venous thromboembolism (690 vs. 840 per 100,000) and incisional hernia (710 vs. 8,800 per 100,000), but a higher rate of vaginal cuff dehiscence (640 vs. 290 per 100,000). Laparoscopic hysterectomy resulted in more quality-adjusted life years (499,171 vs. 490,711 over five years).

Corresponding author: Matthew T. Siedhoff, MD, MSCR, University of North Carolina at Chapel Hill Dept OBGYN, Campus Box 7570, 4010 Old Clinic Bldg, Chapel Hill, NC 27599-7570, matthew_siedhoff@med.unc.edu (o) 919.966.7764 (f) 919.966.5833.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest: The authors (all authors) report no conflicts of interest.

These data were presented at the 43rd AAGL Global Congress of Minimally Invasive Gynecology, Nov 19 (17-21), 2014. Vancouver, BC.

Conclusion—The risk of leiomyosarcoma morcellation is balanced by procedure-related complications associated with laparotomy, including death. This analysis provides patients and surgeons with estimates of risk and benefit, upon which patient-centered decisions can be made.

Keywords

Abdominal Hysterectomy; Laparoscopic Hysterectomy; Morcellation; Uterine fibroids

Introduction

Hysterectomy is the most common procedure performed in non-pregnant women in the United States, with leiomyomata (fibroids) the indication for a significant proportion of these.¹ Surgeons are increasingly employing laparoscopy for hysterectomy.² For all laparoscopic supracervical hysterectomies and total laparoscopic hysterectomies where the specimen is too large to be removed intact vaginally, the uterus must be morcellated—i.e. cut into pieces which will fit through small incisions. If morcellation is not contained in a retrieval bag, tissue may be unintentionally left behind, which can lead to spread of benign or malignant tissue.^{3,4}

Morcellation has come under scrutiny regarding the risk of disseminating occult leiomyosarcoma, highlighted by a recent Food and Drug Administration safety notification.⁵ Unlike other gynecologic malignancies, leiomyosarcoma is difficult to distinguish from benign disease preoperatively and bears a poor prognosis.⁶ Retrospective studies suggest a worse prognosis with morcellation of leiomyosarcoma compared to intact removal of the uterus.^{7,8}

Laparoscopic hysterectomy affords shorter hospital stay and convalescence compared to abdominal hysterectomy. In addition, laparoscopic hysterectomy is associated with less pain, lower blood loss, and lower rates of wound infection, incisional hernia, and venous thromboembolism.⁹ On the other hand, abdominal hysterectomy avoids the risk of morcellating leiomyosarcoma. To provide physicians with better estimates of health outcomes when considering these surgical approaches, we conducted a decision analysis comparing laparoscopic hysterectomy to abdominal hysterectomy for the management of the enlarged uterus with presumed benign leiomyomata in premenopausal women, examining mortality, surgical complications, and quality of life.

Materials and Methods

We constructed a decision tree to compare outcomes of laparoscopic hysterectomy with morcellation to abdominal hysterectomy for women with an enlarged uterus due to presumed benign leiomyomata (Figure 1). We assessed a hypothetical cohort of 100,000 premenopausal women, as approximately 200,000 hysterectomies are performed for leiomyomata annually in the United States.¹ It made clinical sense that roughly half of those could involve uteri large enough to require morcellation if considered for laparoscopic hysterectomy. The decision tree model was constructed using Excel™ 2010 (Microsoft Corp, Redmond, Washington) and TreePlan™ (TreePlan Software, San Francisco, California).

Women undergoing both laparoscopic and abdominal hysterectomy were at risk for potential surgical complications, each represented as unique and independent health states in the model. Morbidity and mortality outcomes were evaluated over a 5-year time horizon. This study was considered exempt from review by the Institutional Review Board at the University of North Carolina at Chapel Hill as it involved analysis of existing published data. S.W., S.R., and M.S. were responsible for analyzing data.

Base-case estimates and ranges for each parameter, as well as transition probabilities governing movement between branches in the decision tree, were determined by published literature review (Table 1). In selecting estimates, preference was given to higher quality studies and more recent publications, reflecting advances in surgical practice. Surgical complications in the model included transfusion, abdominal wound infection, vaginal cuff dehiscence, venous thromboembolism, incisional hernia, leiomyosarcoma, death from leiomyosarcoma, and death from hysterectomy. Febrile episodes and vaginal cuff infections were considered but felt better represented by identifiable and more objective diagnoses, wound infection and cuff dehiscence. Major visceral and vascular adverse events were not included as they are rare and not significantly different between laparoscopic and abdominal hysterectomy.¹⁰

Mortality rates due to hysterectomy were reflected in the literature as a short-term outcome and were not categorized by a specific cause (e.g. fatal embolic event). Excluding older studies conducted when safety and prophylactic measures (e.g. infection, venous thromboembolism) were different from modern practice,^{11,12} estimates of 0.00012 (laparoscopic hysterectomy) and 0.00032 (abdominal hysterectomy) were derived from three larger and more recent series.¹³⁻¹⁵

In terms of occult malignancy, we focused on leiomyosarcoma in particular as it mimics benign myomatous disease. Other more rare uterine mesenchymal tumors have diverse biologic behavior and the impact of morcellation on these tumors is unknown. Cervical cancer is almost always a known preoperative diagnosis, and the risk of tissue dissemination appears to be less serious with endometrial cancer.¹⁶ Ten sources were considered regarding the incidence of leiomyosarcoma among women undergoing hysterectomy for presumed fibroids (Table 2).^{4, 17-25} Quality and the degree to which the study population mirrored that for our decision analysis was evaluated based on year of publication, menopausal status, number of subjects, geographical location, and pathologic criteria used to determine leiomyosarcoma diagnosis. An estimate of 0.0012 (6/5084) was derived from what were considered the four highest quality sources, reporting mean estimates of 0.0008,¹⁹ 0.0007,²² 0.0009,⁴ and 0.0023.²³ The range for sensitivity analysis included those with sample size greater than 1,000: 0.0007²² to 0.0049.¹⁷

Leiomyosarcoma mortality estimates were derived from Surveillance, Epidemiology, and End Results reports.²⁶ First, we assumed women with metastatic disease would generally be identified pre-operatively and not candidates for our hypothetical cohort. In rare cases when it was not, surgical approach, with or without morcellation, would not change their stage (IV) and nor impact overall survival, which would be driven by the distant metastases. Therefore, occult leiomyosarcoma detected at the time of hysterectomy would be

represented in the model by an International Federation of Obstetrics and Gynecology stage I or stage II (confined to the pelvis) diagnosis, with a 5-year mortality of 0.59. Second, we assumed morcellation could lend the same prognosis as spontaneous cancer spread, and thus the laparoscopic group was assigned a stage III (extra-pelvic disease) prognosis, with a 5-year mortality of 0.72 (i.e. all laparoscopic patients given a worse prognosis than abdominal patients).

In the model, morcellation indicated the cutting of uterine tissue to facilitate laparoscopic removal. Data are lacking regarding safety differences between various morcellation techniques, preventing stratification by type of morcellation. The few studies which demonstrate survival differences in leiomyosarcoma patients who underwent surgery with and without morcellation include a heterogeneous set of extraction modalities.^{7,8}

Health state utilities capture health-related quality of life and are measured on a scale of 0 to 1, where 0 represents death and 1 represents 1 year of life in perfect health. Each year of life spent at that health state can then be quantified in quality-adjusted life years. Using published literature, we derived utility estimates for each health state represented in the model as well as the average duration of each health state (Table 3).

To account for the possibility of experiencing multiple clinical events, each with varying duration and morbidity, we divided the 5-year (60-month) period into 1-month increments and used a selective weighted average to calculate 1-month utilities for each distinct pathway in the tree. We then summed across 5-years to obtain 5-year quality-adjusted life years for the laparoscopic and abdominal branches. To more accurately reflect real-world clinical scenarios, the model was built to reflect the fact that women could experience multiple clinical adverse events simultaneously (e.g., require a transfusion and have a wound infection). If events overlapped in time, the worse utility estimate was assigned for that period. We further assumed that death due to hysterectomy occurred immediately post-operatively—i.e., at the beginning of our study window. Accordingly, these persons contributed a utility weight of 0 to the model. For leiomyosarcoma-related deaths, these persons experience the quality-adjusted life-years associated with first- and second-line chemotherapy, as well as subsequent palliative care, and are assumed to die in year 5 of the model, using 5-year survival estimates.

Deterministic (one-way univariate) sensitivity analyses were performed to assess the robustness of the assumptions in the decision model,²⁷ including surgical complications, the probability of leiomyosarcoma, and probability of death from hysterectomy. The range of clinical outcomes (e.g. transfusion, wound infection, etc.) was evaluated by varying the input for each clinical event to its minimum and maximum. Given the limited reports on utilities for the health states in our model, we performed a sensitivity analysis by varying the utility by 20% higher and lower than each base-case estimate.

Results

The decision analysis predicted fewer overall deaths with laparoscopic hysterectomy compared to abdominal hysterectomy (98 vs. 103 per 100,000) (Table 4). While there were

more deaths from leiomyosarcoma following laparoscopic hysterectomy (86 vs. 71 per 100,000), there were more hysterectomy-related deaths with abdominal hysterectomy (32 vs. 12 per 100,000). For surgical complications, the laparoscopic group had lower rates of transfusion (2,400 vs. 4,700 per 100,000), wound infection (1,500 vs. 6,300 per 100,000), venous thromboembolism (690 vs. 840 per 100,000) and incisional hernia (710 vs. 8,800 per 100,000), but a higher rate of vaginal cuff dehiscence (640 vs. 290 per 100,000), compared to the abdominal group.

In terms of quality of life, the laparoscopic group resulted in 499,171 quality-adjusted life years, compared to 490,711 in the abdominal group (incremental difference: 8,460 additional quality-adjusted life years gained among women undergoing laparoscopic hysterectomy). Stated another way, on average, women undergoing laparoscopic hysterectomy experience an additional 0.85 quality-adjusted life years over 5 years (1.02 months), compared to women undergoing abdominal hysterectomy.

In the sensitivity analysis, our results were relatively robust to varying risks of postoperative complications, leiomyosarcoma, and hysterectomy-associated deaths across predefined ranges in the published literature (Table 4). Using the lowest estimate of leiomyosarcoma (0.007), the incremental difference in the number of deaths per 100,000 ranged from 11 to 19 more with abdominal hysterectomy, varying the rate of procedure-related death. With the high estimate (0.0049), the number ranged from 36 to 44 more deaths with laparoscopic hysterectomy. The incremental difference in death associated with laparoscopic hysterectomy was most conservative with the base-case estimates of procedure-related death (Figure 2). A hypothetical leiomyosarcoma incidence of 0.0015 would provide equivalent mortality between laparoscopic and abdominal groups, assuming base-case estimate for procedure-related death.

Quality-adjusted life year differences were robust across a $\pm 20\%$ utility range for sensitivity analysis. For example, if the hysterectomy utility estimate was, in fact, 0.72 rather than 0.9, the difference in total quality-adjusted life years over 5 years would be 16,438, with laparoscopic hysterectomy patients experiencing an additional 0.16 quality-adjusted life years over 5 years (1.97 months). Even without a decrement for hysterectomy, there remained a difference of 4,312 quality-adjusted life years (0.52 months). There was no scenario where a 20% adjustment in base-case utility resulted in more quality-adjusted life years for abdominal hysterectomy.

Comment

Using base-case estimates, our decision analysis predicted lower overall mortality from laparoscopic hysterectomy with morcellation than abdominal hysterectomy for treating the presumed fibroid uterus in premenopausal women. Abdominal hysterectomy was associated with more postoperative complications and lower quality of life.

A strength of the study includes its design as a decision analysis, a strategy particularly helpful when a comparative prospective study is challenging. In this case, it would not be feasible to conduct a randomized trial comparing laparoscopic hysterectomy with

morcellation to abdominal hysterectomy because leiomyosarcoma is so rare. Further, the analysis incorporated mortality due to the procedure itself, not simply mortality associated with morcellation of leiomyosarcoma. Insight was also provided for multiple clinical outcomes, offering more information to guide surgeons in counseling women on approach for hysterectomy for fibroids. Lastly, outcomes were assessed by comprehensive literature review, and sensitivity analyses supported the model's conclusions, adding confidence to the applicability of these findings to a clinical setting.

Any discussion of risk associated with morcellation of presumed leiomyomata is limited by the paucity of data regarding the incidence of occult leiomyosarcoma in this setting. Currently available reports include very small numerators and denominators when considering the high number of uterine surgeries for fibroids that occurred during the respective time periods.^{4, 17-25} The studies span several decades, with varying pathologic criteria to define leiomyosarcoma, and include data from five different countries. Some women in the reports were identified preoperatively and some included older, postmenopausal women. The population, therefore, does not necessarily reflect those at risk, as morcellation would not have been performed in the first place. Thus, limitations in the literature suggest our estimate was conservative, and updated estimates of leiomyosarcoma risk in this population are unlikely to alter the direction of our conclusions. Although the high end of leiomyosarcoma incidence in sensitivity analysis changed the direction of favorable mortality to abdominal hysterectomy, consideration of all the available literature suggests it is fair to at least grant near-equivalent mortality, with outcomes other than mortality still clearly favoring laparoscopy. Further, our estimates of mortality from the procedure itself were the most conservative of the candidates available in sensitivity analysis.

Data are limited regarding the specific impact of morcellation of occult leiomyosarcoma. The model assumed the behavior of a morcellated leiomyosarcoma would mimic that of spontaneous disease spread. A better understanding of the impact of leiomyosarcoma morcellation could alter the conclusions of our model, either positively or negatively.

The results are subject to uncertainty in the estimates of rare events such mortality. In particular, in the absence of randomization, unmeasured factors could influence the relationship between type of surgery and death. Further, randomized trials involving the specific target population were not always available, so we attempted to account for this uncertainty by conducting sensitivity analyses, varying point estimates of these events with ranges reported in existing literature.

Data were also limited in assigning utilities to various complications associated with hysterectomy, but our findings were robust to a 20% manipulation of the estimates. In all scenarios, laparoscopic hysterectomy was favored in terms of quality of life.

Finally, this analysis was conducted specifically on clinical outcomes. Assessing cost associated with surgery is notoriously difficult, but monetary estimates for the procedure and associated post-operative events could add depth to the consideration of approach for hysterectomy to treat leiomyomata. Not all clinical outcomes were assessed, but more recent

literature suggests the rate of visceral injury is not different between laparoscopic and abdominal hysterectomy.¹⁰ The outcomes included in our study are not as likely to change based on improvement in technique (e.g. venous thromboembolism), and, if anything, would favor a laparoscopic approach (e.g. blood loss).

Morcellation is currently one of the most debated issues in gynecologic surgery, both in the media and in the medical arena, prompted by a recent Food and Drug Administration safety notification⁵ and the response of several large Obstetrics and Gynecology organizations regarding its use.^{28, 29} The Food and Drug Administration report emphasizes risk associated with morcellation, nearly to the exclusion of the benefits of minimally invasive surgery for leiomyomata.^{9, 15} The benefits could be further improved by reducing risk associated with morcellation (e.g. specimen containment) rather than abandoning minimally invasive treatment for fibroids. Better understanding of risk factors for leiomyosarcoma, new diagnostics to preoperatively distinguish benign from malignant myomata, and enhanced methods of tissue extraction represent potential avenues for improvement in the safety and care of women with uterine disease.

Acknowledgments


Source of funding: None.

References

1. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. *Obstet Gynecol.* 2013; 122:233–41. [PubMed: 23969789]
2. Lee J, Jennings K, Borahay MA, Rodriguez AM, Kilic GS, Snyder RR, et al. Trends in the national distribution of laparoscopic hysterectomies from 2003–2010. *J Minim Invasive Gynecol.* 2014; 21:656–61. [PubMed: 24462854]
3. Leren V, Langebrenne A, Qvigstad E. Parasitic leiomyomas after laparoscopic surgery with morcellation. *Acta Obstet Gynecol Scand.* 2012; 91:1233–6. [PubMed: 22574911]
4. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. *PLoS One.* 2012; 7:50058.
5. [April 17, 2014] Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication.. Food and Drug Administration. 2014. (at <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm>.)
6. Vilos GA, Marks J, Ettl HC, Vilos AG, Prefontaine M, Abu-Rafea B. Uterine smooth muscle tumors of uncertain malignant potential: Diagnostic challenges and therapeutic dilemmas. A report of 2 cases and review of the literature. *J Minim Invasive Gynecol.* 2012; 19:288–95. [PubMed: 22546421]
7. Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. *Gynecol Oncol.* 2011; 122:255–9. [PubMed: 21565389]
8. George S, Barysaukas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. *Cancer.* Jun 12, 2014 [Epub ahead of print].
9. Nieboer TE, Johnson N, Lethaby A, Tavender E, Curr E, Garry R, et al. Surgical approach to hysterectomy for benign gynaecological disease. *Cochrane Database Syst Rev.* 2009; 8:CD003677.
10. Brummer TH, Jalkanen J, Fraser J, Heikkinen AM, Kauko M, Mäkinen J, Seppälä T, Sjöberg J, Tomás E, Härkki P. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. *Hum Reprod.* Jul. 2011; 26(7):1741–51. [PubMed: 21540244]

11. Loft A, Andersen TF, Bronnum-Hansen H, Roepstorff C, Madsen M. Early postoperative mortality following hysterectomy. A Danish population based study, 1977-1981. *Br J Obstet Gynaecol.* 1991; 98:147–54. [PubMed: 1822955]
12. Wingo PA, Huzar CM, Rubin GL, Ory HW, Peterson HB. The mortality risk associated with hysterectomy. *Am J Obstet Gynecol.* 1985; 152:803–8. [PubMed: 4025434]
13. McPherson K, Metcalfe MA, Herbert A, Maresh M, Casbard A, Hargreaves J, et al. Severe complications of hysterectomy: The VALUE study. *BJOG.* 2004; 111:688–94. [PubMed: 15198759]
14. Wallenstein MR, Ananth CV, Kim JH, Burke WM, Hershman DL, Lewin SN, et al. Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. *Obstet Gynecol.* 2012; 119:709–16. [PubMed: 22433333]
15. Wisner A, Holcroft CA, Tolandi T, Abenhaim HA. Abdominal versus laparoscopic hysterectomies for benign diseases: Evaluation of morbidity and mortality among 465,798 cases. *Gynecological surgery.* 2013; 10:117–22.
16. Hill AJ, Carroll AW, Matthews CA. Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicocapexy for uterine prolapse. *Female Pelvic Med Reconstr Surg.* 2014; 20:113–5. [PubMed: 24566217]
17. Leibsohn S, d'Ablaing G, Mishell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. *Am J Obstet Gynecol.* 1990; 162:968–76. [PubMed: 2327466]
18. Reiter RC, Wagner PL, Gambone JC. Routine hysterectomy for large asymptomatic uterine leiomyomata: A reappraisal. *Obstet Gynecol.* 1992; 79:481–4. [PubMed: 1553162]
19. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. *Obstet Gynecol.* 1994; 83:414–8. [PubMed: 8127535]
20. Takamizawa S, Minakami H, Usui R, Noguchi S, Ohwada M, Suzuki M, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. *Gynecol Obstet Invest.* 1999; 48:193–6. [PubMed: 10545745]
21. Sinha R, Hegde A, Mahajan C, Dubey N, Sundaram M. Laparoscopic myomectomy: Do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy? *J Minim Invasive Gynecol.* 2008; 15:292–300. [PubMed: 18439500]
22. Kamikabeya TS, Etchebehere RM, Nomelini RS, Murta EF. Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital. *European journal of gynaecological oncology.* 2010; 31:651–3. [PubMed: 21319509]
23. Leung F, Terzibachian JJ. Re: “The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma”. *Gynecol Oncol.* 2012; 124:172–3. [PubMed: 21955481]
24. Rowland M, Lesnock J, Edwards R, Richard S, Zorn K, Sukumvanich P. Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation. *Gynecologic oncology.* 2012; 127:29.
25. Theben JU, Schellong AR, Altgassen C, Kelling K, Schneider S, Grosse-Drieling D. Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): An analysis of 1,584 LASH cases. *Arch Gynecol Obstet.* Mar. 2013; 287:455–62. [PubMed: 23053310]
26. Kosary, CL. SEER survival monograph: Cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics.. In: Ries, LAG.; Young, JL.; Keel, GE.; Eisner, MP.; Lin, DY.; Horner, MD., editors. *Cancer of the corpus uteri.* National Cancer Institute, SEER Program, NIH; Bethesda (MD): 2007. p. 123-32.
27. Briggs AH. Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics.* 2000; 17:479–500. [PubMed: 10977389]
28. [May 9, 2014] Power morcellation and occult malignancy in gynecologic surgery: A special report.. The American Congress of Obstetricians and Gynecologists. 2014. (at: http://www.acog.org/Resources_And_Publications/Task_Force_and_Work_Group_Reports/Power_Morcellation_and_Occult_Malignancy_in_Gynecologic_Surgery.)

29. AAGL Advancing Minimally Invasive Gynecologic Surgery Worldwide. AAGL Practice Report: Morcellation during uterine tissue extraction. *J Minim Invasive Gynecol.* 2014; 21:517–30. [PubMed: 24865630]
30. Hur HC, Donnellan N, Mansuria S, Barber RE, Guido R, Lee T. Vaginal cuff dehiscence after different modes of hysterectomy. *Obstet Gynecol.* 2011; 118:794–801. [PubMed: 21934442]
31. Koo YJ, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Vaginal cuff dehiscence after hysterectomy. *Int J Gynaecol Obstet.* 2013; 122:248–52. [PubMed: 23800718]
32. Uccella S, Ceccaroni M, Cromi A, Malzoni M, Berretta R, De Iaco P, et al. Vaginal cuff dehiscence in a series of 12,398 hysterectomies: Effect of different types of colpotomy and vaginal closure. *Obstet Gynecol.* 2012; 120:516–23. [PubMed: 22914459]
33. Ritch JM, Kim JH, Lewin SN, Burke WM, Sun X, Herzog TJ, et al. Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy. *Obstet Gynecol.* 2011; 117:1367–74. [PubMed: 21606747]
34. Harkki-Siren P, Sjoberg J, Kurki T. Major complications of laparoscopy: A follow-up Finnish study. *Obstet Gynecol.* 1999; 94:94–8. [PubMed: 10389725]
35. Brown SR, Goodfellow PB. Transverse versus midline incisions for abdominal surgery. *Cochrane Database Syst Rev.* 2005; 4:CD005199. [PubMed: 16235395]
36. Bickenbach KA, Karanicolas PJ, Ammori JB, Jayaraman S, Winter JM, Fields RC, et al. Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery. *Am J Surg.* 2013; 206:400–9. [PubMed: 23570737]
37. Le Huu Nho R, Mege D, Ouaiissi M, Sielezneck I, Sastre B. Incidence and prevention of ventral incisional hernia. *J Visc Surg.* 2012; 149:3–14.
38. Hussain A, Mahmood H, Singhal T, Balakrishnan S, Nicholls J, El-Hasani S. Long-term study of port-site incisional hernia after laparoscopic procedures. *JSLs.* 2009; 13:346–9. [PubMed: 19793475]
39. Swank HA, Mulder IM, la Chapelle CF, Reitsma JB, Lange JF, Bemelman WA. Systematic review of trocar-site hernia. *Br J Surg.* 2012; 99:315–23. [PubMed: 22213083]
40. O'Sullivan AK, Thompson D, Chu P, Lee DW, Stewart EA, Weinstein MC. Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. *Int J Technol Assess Health Care.* 2009; 25:14–25. [PubMed: 19126247]
41. Klarenbach S, Manns B, Reiman T, Reaume MN, Lee H, Lloyd A, et al. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. *Cancer.* 2010; 116:3224–32. [PubMed: 20564645]
42. Chatterjee A, Krishnan NM, Rosen JM. Complex ventral hernia repair using components separation with or without synthetic mesh: A cost-utility analysis. *Plast Reconstr Surg.* 2014; 133:137–46. [PubMed: 24374673]
43. Spangler EL, Dillavou ED, Smith KJ. Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. *J Vasc Surg.* 2010; 52:1537–45. [PubMed: 20843631]
44. Hynes DM, Stroupe KT, Luo P, Giobbie-Hurder A, Reda D, Kraft M, et al. Cost effectiveness of laparoscopic versus open mesh hernia operation: Results of a department of veterans affairs randomized clinical trial. *J Am Coll Surg.* 2006; 203:447–57. [PubMed: 17000387]
45. Reichardt P, Leahy M, Garcia Del Muro X, Ferrari S, Martin J, Gelderblom H, et al. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The sarcoma treatment and burden of illness in north america and europe (SABINE) study. *Sarcoma.* 2012; 2012:740279. [PubMed: 22550425]
46. Health Quality Ontario. KRAS testing for anti-EGFR therapy in advanced colorectal cancer: An evidence-based and economic analysis. *Ont Health Technol Assess Ser.* 2010; 10:1–49.



†In all possible branches, an individual could have an immediate post-operative death due to hysterectomy
 * Immediate surgical complications include: need for transfusion, abdominal wound infection, and vaginal cuff dehiscence
 ** Longer-term surgical complications include: venous thromboembolism and hernia

Figure 1. Decision Tree

Premenopausal women requiring hysterectomy for an enlarged uterus could undergo laparoscopic or abdominal hysterectomy. In either approach, death could occur immediately after the procedure. Women who survive the procedure could experience immediate surgical complications (blood transfusion, wound infection, or vaginal cuff dehiscence) and/or longer term surgical complications (hernia and venous thromboembolism). Women who had occult leiomyosarcoma at the time of the procedure would undergo treatment, after which point they could recover or die (sarcoma-related death).




Figure 2. Number of incremental deaths per 100,000 associated with laparoscopic hysterectomy by varying the candidates for leiomyosarcoma incidence used in the sensitivity analysis. At incidence of 0.007, 0.008, 0.009, and 0.0013, there were more deaths per 100,000 associated with abdominal hysterectomy. At incidence of 0.023, 0.027, and 0.049, there were more deaths per 100,000 associated with laparoscopic hysterectomy. (A) Base-case estimate: abdominal hysterectomy mortality 0.00032, laparoscopic hysterectomy mortality 0.00012. (B) Sensitivity analysis estimate #1: abdominal hysterectomy mortality 0.00038, laparoscopic hysterectomy mortality 0.00012. (C) Sensitivity analysis estimate #2: abdominal hysterectomy mortality 0.00038, laparoscopic hysterectomy mortality 0.000096. (D) Sensitivity analysis estimate #3 abdominal hysterectomy mortality 0.00032, laparoscopic hysterectomy mortality 0.000096.

Table 1

Parameter estimates, hysterectomy for presumed leiomyomata

Parameter	Laparoscopic Hysterectomy Estimate	Range	Abdominal Hysterectomy Estimate	Range	Sources	Level of Evidence ^g
Transfusion	0.024	[0.013, 0.035]	0.047	[0.043, 0.047]	Wiser, Nieboer, Wallenstein ^{15,9,14}	I
Wound infection	0.015	[0.00055, 0.015]	0.063	Not varied	Nieboer, Wallenstein ^{9,14}	I
Vaginal cuff dehiscence ^a	0.0064	[0.0002, 0.0089]	0.0029	[0.0015, 0.006]	Hur, Koo, Ucella ³⁰⁻³²	II-2
Venous thromboembolism	0.0069	[0.003, 0.009]	0.0084	[0.0072, 0.0084]	Wiser, Nieboer, Ritch, Harrki-Siren, Wallenstein ^{15,9,33,34,14}	I
Hernia ^b	0.0071	[0.0014, 0.09]	0.0880	[0.045, 0.098]	Brown, Bickenbach, Le Huu Nho, Hussain, Swank ³⁵⁻³⁹	I
Occult leiomyosarcoma incidence ^c	0.0012	[0.0007, 0.0049]	--	--	Parker, Leung, Kamikabeya, Seidman, Leibsohn ^{19,22,33,4,17}	II-3
Procedure-related death	0.00012	[0.000096, 0.00012]	0.00032	[0.00032, 0.00038]	Wiser, Wallenstein ^e , McPherson ^{f,3-15}	II-3
Death from leiomyosarcoma ^d	0.72	Not varied	0.59	Not varied	Kosary ²⁶	III

^a A weighted average was used as the incidence was low and the difference varied between groups among candidate studies.^b It was assumed most candidate fibroid uteri large enough to need morcellation during laparoscopic hysterectomy would require a vertical midline incision if removed via laparotomy. The rate of incisional hernia after hysterectomy was not readily identified in the gynecologic literature and was thus extrapolated from general surgery reports. The incidence of hernia with a transverse incision reported in a Cochrane review was used for the lower estimate in sensitivity analysis.^c The same estimate and range was used for the incidence of occult leiomyosarcoma in laparoscopic and abdominal hysterectomy.^d The abdominal hysterectomy group was assigned the 5-year death rate for International Federation of Obstetrics and Gynecology stage I-II leiomyosarcoma and laparoscopic hysterectomy that for stage III leiomyosarcoma according to Surveillance, Epidemiology, and End Results reports.^e Wallenstein et al was used only for the laparoscopic hysterectomy estimate

McPherson et al. was used only for the abdominal hysterectomy estimate
U.S. Preventative Services Task Force level of evidence for highest-quality source,

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Rate of leiomyosarcoma for women undergoing surgery for presumed fibroids

Study	Publication Year	Study Years	Country	Age (yrs)	Leiomyosarcoma cases	Total patients	Rate of leiomyosarcoma
Leibsohn ¹⁷	1990	1983-1988	USA	36-62	7	1,429	0.0049
Reiter ¹⁸	1992	1986-1989	USA	42 (mean)	0	104	0.0
Parker ^{*19}	1994	1988-1992	USA	22-86	1	1,332	0.0008
Takamizawa ²⁰	1999	1983-1997	Japan	26-75	1	923	0.0011
Sinha ^{*21}	2008	1998-2005	India	34 (mean)	2	505	0.0040
Kamikabeya ²²	2010	1987-2008	Brazil	Not reported	1	1,364	0.0007
Rowland ^{†24}	2011	2006-2011	USA	Not reported	3	1,115	0.0027
Leung ²³	2012	1999-2005	France	34-77	3	1,297	0.0023
Seidman ^{*‡4}	2012	1999-2010	USA	Not reported	1	1,091	0.0009
Theben ²⁵	2013	2005-2010	Germany	28-81	2	1,584	0.0013

* Included myomectomies

† Abstract only

‡ Denominator included only morcellated cases

Table 3

Utilities

Parameter	Estimate	Range *	Duration (months)	Source
Hysterectomy for fibroids ^a	0.9	[0.72, 1.0]	6	O'Sullivan ⁴⁰
Transfusion	0.48	[0.38, 0.58]	1	Klarenbock ⁴¹
Wound infection	0.607	[0.49, 0.73]	1	Chatterjee ⁴²
Vaginal cuff dehiscence	0.54	[0.43, 0.65]	1	Chatterjee ⁴²
Venous thromboembolism	0.8	[0.64, 0.96]	12	Spangler ⁴³
Hernia	0.77	[0.62, 0.92]	24	Hynes ⁴⁴
Leiomyosarcoma (1 st 6 months chemotherapy) ^b	0.76	[0.61, 0.91]	6	Reichardt ⁴⁵
Leiomyosarcoma progression (additional 12-months chemotherapy) ^c	0.66	[0.53, 0.79]	12	Reichardt ⁴⁵
Leiomyosarcoma progression (palliative care) ^d	0.71	[0.57, 0.85]	36	Health Quality Ontario ⁴⁶
Alive	1.0	Not varied	Varies	

* Range based on +/- 20% of base-case utility. If +20% exceeded 1.0, the utility was assigned a value of 1.0

^aDecrement applied only to abdominal hysterectomy

^bFor women with leiomyosarcoma diagnosed at time of surgery, we presumed all would receive a minimum 6 months of chemotherapy (approximately 6 cycles). Responders would get no more treatment and return to normal health.

^cNon-responders after 6 months would get additional chemotherapy (up to 12 months).

^dNon-responders after 12 months of chemotherapy would go on to palliative care and ultimately die of their disease

Table 4

Clinical outcomes: per 100,000 women undergoing hysterectomy for presumed fibroids

Outcome	Laparoscopic hysterectomy: Base-case [range] *	Abdominal hysterectomy: Base-case [range] *	Incremental Difference (Laparoscopic–abdominal)
Leiomyosarcoma cases	120	120	n/a
Leiomyosarcoma deaths	86 [50-353]	71 [41-289]	15
Hysterectomy-related deaths	12 [10-12]	32 [28-32]	-20
Total deaths	98 [60-365]	103 [69-321]	-5
Transfusion	2,400 [1,300-3,500]	4,700 [4,300-4,700]	-2,300
Venous thromboembolism	690 [30-900]	840 [720-840]	-150
Vaginal cuff dehiscence	640 [200-890]	290 [150-600]	350
Abdominal wound infection	1,500 [55-1,500]	6,300 [6,300]	-4,800
Hernia	710 [140-900]	4,500 [4,500-9,800]	-8,090
Quality-adjusted life years	499,171 [499,062-499,280]	490,711 [482,733-486,270]	8,460

* Sensitivity analyses were conducted using the ranges outlined in Tables 1 and 3, i.e. the one-way sensitivity analysis for each input

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript